Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug;104(8):e356-e359.
doi: 10.3324/haematol.2018.207548. Epub 2019 Feb 21.

Long-term follow up after third-party viral-specific cytotoxic lymphocytes for immunosuppression- and Epstein-Barr virus-associated lymphoproliferative disease

Sajida Kazi  1 , Abhinav Mathur  2 , Gwen Wilkie  3 , Kirsty Cheal  4 , Richard Battle  3 , Neil McGowan  3 , Neil Fraser  4 , Emily Hargreaves  3 , David Turner  3 , John D M Campbell  3 , Marc Turner  3 , Mark A Vickers  5   2   4
Affiliations

Long-term follow up after third-party viral-specific cytotoxic lymphocytes for immunosuppression- and Epstein-Barr virus-associated lymphoproliferative disease

Sajida Kazi et al. Haematologica. 2019 Aug.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier survival curves and response rates by number of HLA matches. Kaplan-Meier survival curves plotted against time from end of infusions. (A) Data from all 59 patients. (B) Data split by non-transplant, solid organ transplant and hematopoietic stem cell transplant. No deaths after one year of infusion were ascribable directly to post-transplant lymphoproliferative disease (PTLD). (C) The proportion of patients exhibiting a clinical response, either complete response (CR) or partial response (PR), are plotted against number of HLA matches achieved.
See this image and copyright information in PMC

References

    1. Cesaro S, Pegoraro A, Tridello G, et al. A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation. Transplantation. 2010;89(12):1533–1540. - PubMed
    1. Weiner C, Weintraub L, Wistinghausen B, et al. Graft rejection in pediatric liver transplant patients with Epstein-Barr viremia and post-transplant lymphoproliferative disease. Pediatr Transplant. 2012; 16(5):458–464. - PubMed
    1. Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis. 2009;11(5):383–392. - PubMed
    1. Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol. 2010;149(5):693–705. - PubMed
    1. Uhlin M, Wikell H, Sundin M, et al. Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014;99(2):346–352. - PMC - PubMed

MeSH terms